{"transactions":[{"id":3674402,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-05T18:33:25.000Z","date":"2019-02-01","kind":"exercise","acquired":false,"shares":3400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":10200,"derivative":{"underlying":"Common Stock","underlying_shares":3400},"source":{"system":"sec-edgar","filing":"0001209191-19-007489","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919119007489/doc4.xml","form_type":"4"}},{"id":3674401,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Common Stock","published_at":"2019-02-05T18:33:25.000Z","date":"2019-02-01","kind":"tax_withholding","acquired":false,"shares":1114,"price":6.96,"value":7753.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":141729,"source":{"system":"sec-edgar","filing":"0001209191-19-007489","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919119007489/doc4.xml","form_type":"4"}},{"id":3674400,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Common Stock","published_at":"2019-02-05T18:33:25.000Z","date":"2019-02-01","kind":"exercise","acquired":true,"shares":3400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":142843,"source":{"system":"sec-edgar","filing":"0001209191-19-007489","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919119007489/doc4.xml","form_type":"4"}},{"id":3721347,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Restricted Stock Units","published_at":"2018-12-21T07:29:55.000Z","date":"2018-12-18","kind":"exercise","acquired":false,"shares":1625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On December 18, 2015, the reporting person was granted 6,500 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On December 18, 2015, the reporting person was granted 6,500 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":1625,"derivative":{"underlying":"Common Stock","underlying_shares":1625},"source":{"system":"sec-edgar","filing":"0001209191-18-063801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118063801/doc4.xml","form_type":"4"}},{"id":3721346,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Common Stock","published_at":"2018-12-21T07:29:55.000Z","date":"2018-12-18","kind":"tax_withholding","acquired":false,"shares":446,"price":6.3,"value":2809.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":139443,"source":{"system":"sec-edgar","filing":"0001209191-18-063801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118063801/doc4.xml","form_type":"4"}},{"id":3721345,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Common Stock","published_at":"2018-12-21T07:29:55.000Z","date":"2018-12-18","kind":"exercise","acquired":true,"shares":1625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":139889,"source":{"system":"sec-edgar","filing":"0001209191-18-063801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118063801/doc4.xml","form_type":"4"}},{"id":3727019,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Restricted Stock Units","published_at":"2018-12-18T20:51:58.000Z","date":"2018-12-15","kind":"exercise","acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":2600,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001209191-18-063368","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118063368/doc4.xml","form_type":"4"}},{"id":3727018,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Common Stock","published_at":"2018-12-18T20:51:58.000Z","date":"2018-12-15","kind":"tax_withholding","acquired":false,"shares":357,"price":7.31,"value":2609.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":138264,"source":{"system":"sec-edgar","filing":"0001209191-18-063368","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118063368/doc4.xml","form_type":"4"}},{"id":3727017,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Common Stock","published_at":"2018-12-18T20:51:58.000Z","date":"2018-12-15","kind":"exercise","acquired":true,"shares":1300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":138621,"source":{"system":"sec-edgar","filing":"0001209191-18-063368","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118063368/doc4.xml","form_type":"4"}},{"id":3941109,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Restricted Stock Units","published_at":"2018-05-09T16:19:44.000Z","date":"2018-05-07","kind":"exercise","acquired":false,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units.  50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone.  The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units.  50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone.  The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":3900,"derivative":{"underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001209191-18-028859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118028859/doc4.xml","form_type":"4"}},{"id":3941108,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Common Stock","published_at":"2018-05-09T16:19:44.000Z","date":"2018-05-07","kind":"tax_withholding","acquired":false,"shares":1480,"price":18.1,"value":26788.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":137321,"source":{"system":"sec-edgar","filing":"0001209191-18-028859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118028859/doc4.xml","form_type":"4"}},{"id":3941107,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Common Stock","published_at":"2018-05-09T16:19:44.000Z","date":"2018-05-07","kind":"exercise","acquired":true,"shares":5200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":138801,"source":{"system":"sec-edgar","filing":"0001209191-18-028859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118028859/doc4.xml","form_type":"4"}},{"id":4076382,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Restricted stock units","published_at":"2018-02-05T16:22:20.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":13600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":13600,"derivative":{"underlying":"Common Stock","underlying_shares":13600},"source":{"system":"sec-edgar","filing":"0001209191-18-007472","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118007472/doc4.xml","form_type":"4"}},{"id":4076381,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Reg & Develop Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-02-05T16:22:20.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":47600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":47600,"derivative":{"exercise_price":22.09,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":47600},"source":{"system":"sec-edgar","filing":"0001209191-18-007472","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919118007472/doc4.xml","form_type":"4"}},{"id":4123720,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2017-12-21T16:57:03.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":1625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On December 18, 2015, the reporting person was granted 6,500 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On December 18, 2015, the reporting person was granted 6,500 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":3250,"derivative":{"underlying":"Common Stock","underlying_shares":1625},"source":{"system":"sec-edgar","filing":"0001209191-17-066819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919117066819/doc4.xml","form_type":"4"}},{"id":4123719,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2017-12-21T16:57:03.000Z","date":"2017-12-15","kind":"exercise","acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units, with 50% of the shares underlying the restricted stock units vesting in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units vesting upon the achievement of a specified commercial milestone, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units, with 50% of the shares underlying the restricted stock units vesting in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units vesting upon the achievement of a specified commercial milestone, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":9100,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001209191-17-066819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919117066819/doc4.xml","form_type":"4"}},{"id":4123718,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-12-21T16:57:03.000Z","date":"2017-12-18","kind":"tax_withholding","acquired":false,"shares":494,"price":24.12,"value":11915.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":133601,"source":{"system":"sec-edgar","filing":"0001209191-17-066819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919117066819/doc4.xml","form_type":"4"}},{"id":4123717,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-12-21T16:57:03.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":1625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":134095,"source":{"system":"sec-edgar","filing":"0001209191-17-066819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919117066819/doc4.xml","form_type":"4"}},{"id":4123716,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-12-21T16:57:03.000Z","date":"2017-12-15","kind":"tax_withholding","acquired":false,"shares":395,"price":24.23,"value":9570.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":132470,"source":{"system":"sec-edgar","filing":"0001209191-17-066819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919117066819/doc4.xml","form_type":"4"}},{"id":4123715,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-12-21T16:57:03.000Z","date":"2017-12-15","kind":"exercise","acquired":true,"shares":1300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":132865,"source":{"system":"sec-edgar","filing":"0001209191-17-066819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919117066819/doc4.xml","form_type":"4"}},{"id":4515473,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2016-12-20T18:51:38.000Z","date":"2016-12-18","kind":"exercise","acquired":false,"shares":1625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On December 18, 2015, the reporting person was granted 6,500 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On December 18, 2015, the reporting person was granted 6,500 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":4875,"derivative":{"underlying":"Common Stock","underlying_shares":1625},"source":{"system":"sec-edgar","filing":"0001209191-16-156178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919116156178/doc4.xml","form_type":"4"}},{"id":4515472,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2016-12-20T18:51:38.000Z","date":"2016-12-18","kind":"tax_withholding","acquired":false,"shares":494,"price":31.25,"value":15437.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":131565,"source":{"system":"sec-edgar","filing":"0001209191-16-156178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919116156178/doc4.xml","form_type":"4"}},{"id":4515471,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2016-12-20T18:51:38.000Z","date":"2016-12-18","kind":"exercise","acquired":true,"shares":1625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":132059,"source":{"system":"sec-edgar","filing":"0001209191-16-156178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919116156178/doc4.xml","form_type":"4"}},{"id":4517100,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted stock units","published_at":"2016-12-19T17:22:50.000Z","date":"2016-12-15","kind":"grant","acquired":true,"shares":10400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone."}],"balance_after":10400,"derivative":{"underlying":"Common Stock","underlying_shares":10400},"source":{"system":"sec-edgar","filing":"0001209191-16-155969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919116155969/doc4.xml","form_type":"4"}},{"id":4517099,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":160564,"kind":"person","name":"Powala Christopher","position":1,"cik":"0001654301","reported_name":"Powala Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2016-12-19T17:22:50.000Z","date":"2016-12-15","kind":"grant","acquired":true,"shares":62400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":62400,"derivative":{"exercise_price":28.92,"expiration_date":"2026-12-14","underlying":"Common Stock","underlying_shares":62400},"source":{"system":"sec-edgar","filing":"0001209191-16-155969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654301/000120919116155969/doc4.xml","form_type":"4"}}]}